Pancreatic Cancer Research

ResearcherAsan Medical CenterActive in the last 2 years

Do Hyun Park

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0270-6969; OpenAlex author ID A5011446304. Sources: ClinicalTrials.gov.

Their work

Papers
21 (first author 0, last author 2)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
53
Papers, trials and grants by year

2012: 2 papers · 2013: none · 2014: 1 trial · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 3 papers · 2019: 1 paper · 2020: 4 papers · 2021: 1 paper · 2022: 4 papers · 2023: 2 papers · 2024: 2 papers

Papers 21

  1. Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicen… Co-author DOI 10.1016/j.ejca.2024.114194↗
  2. Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancrea… Co-author DOI 10.1016/j.pan.2024.02.004↗
  3. Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX. Co-author DOI 10.4143/crt.2022.409↗
  4. Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Dam… Co-author DOI 10.4143/crt.2023.452↗
  5. The impact of preoperative EUS-FNA for distal resectable pancreatic cancer: Is it really effective enough to take risks? Co-author DOI 10.1007/s00464-021-08627-3↗
  6. Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1177/17588359221097190↗
  7. Stereotactic Body Radiation Therapy versus Concurrent Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Propensity Score-Matched Analysis. Co-author DOI 10.3390/cancers14051166↗
  8. Clinical outcomes of EUS-guided radiofrequency ablation for unresectable pancreatic cancer: A prospective observational study. Co-author DOI 10.4103/eus-d-21-00049↗
  9. The effect of a newly developed mini-light-emitting diode catheter for interstitial photodynamic therapy in pancreatic cancer xenografts. Last author DOI 10.1186/s12967-021-02900-8↗
  10. Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biom… Co-author DOI 10.1038/s41416-020-0867-x↗
  11. FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma. Co-author DOI 10.1177/1758835920953294↗
  12. EUS-Guided Versus Percutaneous Celiac Neurolysis for the Management of Intractable Pain Due to Unresectable Pancreatic Cancer: A Randomized Clinical Trial. Last author DOI 10.3390/jcm9061666↗
  13. Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.4143/crt.2019.190↗
  14. Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Canc… Co-author DOI 10.3390/cancers11030278↗
  15. Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing. Co-author DOI 10.1007/s10637-017-0497-1↗
  16. Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. Co-author DOI 10.1007/s10637-018-0598-5↗
  17. Contrast-Enhanced Endoscopic Ultrasound for Differentially Diagnosing Autoimmune Pancreatitis and Pancreatic Cancer. Co-author DOI 10.5009/gnl17391↗
  18. Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen. Co-author DOI 10.18632/oncotarget.17940↗
  19. Initial experience of EUS-guided radiofrequency ablation of unresectable pancreatic cancer. Co-author DOI 10.1016/j.gie.2015.08.048↗
  20. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally a… Co-author DOI 10.1016/j.surg.2012.03.010↗
  21. Diagnostic Strategy for Differentiating Autoimmune Pancreatitis From Pancreatic Cancer: Is an Endoscopic Retrograde Pancreatography Essential? Co-author DOI 10.1097/mpa.0b013e31823a509b↗

Trials 1

  1. EUS-guided Biliary Drainage Versus Percutanenous Transhepatic Biliary Darinage for Malignant Biliary Obstruction After Failed ERCP Principal investigator NCT02103413↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tae Jun Song · 17 shared papers, 2016–2024 · strength 1.86
  2. Changhoon Yoo · 14 shared papers, 2017–2024 · strength 1.52
  3. Kyu‐pyo Kim · 13 shared papers, 2017–2024 · strength 1.40
  4. Baek‐Yeol Ryoo · 13 shared papers, 2017–2024 · strength 1.40
  5. Sang Soo Lee · 15 shared papers, 2012–2024 · strength 1.36
  6. Dongwook Oh · 10 shared papers, 2016–2024 · strength 1.28
  7. Song Cheol Kim · 12 shared papers, 2012–2024 · strength 1.17
  8. Myung‐Hwan Kim · 14 shared papers, 2012–2022 · strength 1.16
  9. Dong Wan Seo · 13 shared papers, 2012–2024 · strength 1.15
  10. Ki Byung Song · 11 shared papers, 2017–2024 · strength 1.14
  11. Dae Wook Hwang · 11 shared papers, 2017–2024 · strength 1.14
  12. Jin‐hong Park · 10 shared papers, 2012–2024 · strength 0.97
  13. Woohyung Lee · 4 shared papers, 2020–2023 · strength 0.43
  14. Bong Jun Kwak · 3 shared papers, 2022–2024 · strength 0.42
  15. Seung‐Mo Hong · 3 shared papers, 2018–2024 · strength 0.38
  16. Hyehyun Jeong · 2 shared papers, 2024 · strength 0.35
  17. Inkeun Park · 2 shared papers, 2024 · strength 0.35
  18. Hyunseok Yoon · 2 shared papers, 2023–2024 · strength 0.32
  19. Dong‐Wan Seo · 2 shared papers, 2022 · strength 0.31
  20. Yejong Park · 2 shared papers, 2023–2024 · strength 0.30
  21. Sung‐Hoon Moon · 3 shared papers, 2012–2024 · strength 0.29
  22. So Heun Lee · 2 shared papers, 2022–2023 · strength 0.26
  23. Inhwan Hwang · 3 shared papers, 2018–2020 · strength 0.24
  24. Jaewon Hyung · 2 shared papers, 2020–2023 · strength 0.24
  25. Sang Hyun Shin · 4 shared papers, 2012–2019 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.